A clear-eyed look at the advantages and trade-offs of going public via SPAC merger versus a traditional IPO — so you can make the right decision for your company.
Both paths lead to public markets. The right choice depends on your company's timeline, certainty needs, and growth stage.
| Factor | De-SPAC Merger | Traditional IPO |
|---|---|---|
| Timeline to Listing | 3–5 months | 12–18 months |
| Valuation Certainty | Negotiated upfront | Set by market at pricing |
| Capital Certainty | Trust + PIPE committed | Subject to market conditions |
| Due Diligence Control | Bilateral — both parties review | Underwriter-driven |
| Forward Projections | Can share with investors | Restricted by SEC rules |
| Management Continuity | Typically retained | Typically retained |
| Dilution | Sponsor promote + warrants | Underwriter fees (6–7%) |
| Market Timing Risk | Lower — deal pre-negotiated | High — vulnerable to windows |
| Regulatory Complexity | Proxy + SEC review | S-1 + SEC review |
| Post-Listing Support | Sponsor partner stays involved | Underwriter support fades |
| Minimum Revenue Req. | None — pre-revenue OK | Generally revenue-stage |
| Public Market Education | Built into process | Company must self-educate |
Your market window is closing, a competitor is racing to list, or you need capital quickly to fund growth. A De-SPAC's 3–5 month timeline is unmatched.
If your value proposition depends on forward-looking financials — common in tech, biotech, and high-growth sectors — a De-SPAC lets you share that story.
The right SPAC sponsor provides board expertise, investor relationships, and ongoing capital markets guidance that a traditional underwriter doesn't offer post-IPO.
We'll walk you through the economics, timeline, and structure — with complete transparency.
Schedule a Confidential Call →